Braveheart Bio, Inc. Listed Primary

What the company does

Braveheart Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy ("HCM") and other serious cardiovascular diseases. Its lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor that the company is developing for the treatment of obstructive HCM and non-obstructive HCM. BHB-1893 was initially discovered and developed by Jiangsu Hengrui Pharmaceuticals Co., Ltd. in China and was in-licensed by Braveheart pursuant to an exclusive license agreement with Hengrui. The company was incorporated under the laws of the State of Delaware on May 13, 2024 and began operations in 2025, with principal executive offices in San Francisco, California.

Use of proceeds

We estimate that the net proceeds from the sale of our common stock in this offering will be approximately $351.2 million (or approximately $404.5 million if the underwriters exercise their option to purchase additional shares of common stock in full), based on the initial public offering price of $18.00 per share, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. We currently intend to use the net proceeds, together with existing cash and cash equivalents, to advance the development of BHB-1893 in patients with obstructive hypertrophic cardiomyopathy and non-obstructive hypertrophic cardiomyopathy, to fund research and development personnel and overhead costs to support the advancement of both programs, and to use the remainder for working capital and other general corporate purposes.

Underwriters

Extracted from 424B4 0001628280-26-054354, filed Aug 6, 2026 and verified against that filing text.

Key risk factors

• Broad discretion over use of proceeds

  “We will have broad discretion over the use of proceeds from this offering, including for any purposes described under "Use of Proceeds."”

• No cash dividends expected

  “We have not declared or paid cash dividends on our common stock to date.”

• Exclusive forum provisions in bylaws

  “Our amended and restated bylaws that became effective upon the completion of this offering provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any state law claims for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of, or a claim based on, fiduciary duty owed by any of our current or former directors, officers, and employees to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, our certificate of incorporation or our bylaws (including the interpretation, validity or enforceability thereof), or (iv) any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery of the State of Delaware having personal jurisdiction over the indispensable parties named as defendants therein (the "Delaware Forum Provision").”